For the year ending 2025-12-31, SER had -$616K decrease in cash & cash equivalents over the period. -$18,014K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -19,215 |
| Depreciation and amortization | 73 |
| Loss on disposal of property and equipment | -91 |
| Non-cash lease expense | 203 |
| Non-cash interest expense | 138 |
| Amortization of debt issuance costs and debt discounts | 58 |
| Stock-based compensation | 3,793 |
| Common stock issued to consultant for services rendered | 226 |
| Restricted stock units released to consultant for services rendered | 29 |
| Change in fair value of convertible promissory notes | 0 |
| Change in fair value of warrants liabilities | -4,263 |
| Gain on warrants expiration | 724 |
| Loss on sale of subsidiary | -166 |
| Grant receivable | 0 |
| Prepaid expenses and other assets | -673 |
| Accounts payable | 1,197 |
| Accrued expenses | -231 |
| Other current liabilities | 18 |
| Operating lease liabilities | -187 |
| Net cash used in operating activities | -17,955 |
| Purchase of equipment | 59 |
| Net cash used in investing activities | -59 |
| Proceeds from the issuance of common stock and warrants to juvenescence | 0 |
| Drawdown on loan facilities from juvenescence | 0 |
| Cash and restricted cash acquired in connection with the merger | 0 |
| Proceeds from the exercise of stock options | 15 |
| Proceeds from the exercise of post-merger warrants by juvenescence | 0 |
| Proceeds from issuance of common stock-Juvenescence | 4,916 |
| Principal repayment on loan facilities to juvenescence | 0 |
| Principal repayments on finance lease liabilities | 0 |
| Proceeds from issuance of series a convertible preferred stock, net | 4,940 |
| Proceeds from issuance of common stock-At The Market Offering Program | 2,628 |
| Proceeds from 2025 convertible note, net | 4,913 |
| Net cash provided by financing activities | 17,412 |
| Effect of foreign currency on cash and cash equivalents | -14 |
| Net decrease in cash and cash equivalents | -616 |
| At beginning of the year | 3,672 |
| At end of the year | 3,056 |
Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc. (SER)